Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready
Plant Bioscience Limited has 3 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are spread across 3 distinct art units, meaning every pending matter is in a different specialized unit. The prosecution involves several examiners, with each handling one action. This distribution indicates that the company's current biotechnology applications are being reviewed in entirely separate technical and personnel environments.
REDDEN, KAREN M is the busiest examiner, managing 1 pending office action. Because the 3 pending office actions are split among different individuals and units, there is no concentration of workload. Practitioners must address the unique requirements of each unit to resolve the active matters. The lack of overlap among the 3 distinct examiners means that the outcome of one action is unlikely to influence the others. A tailored approach for each case will be essential for success in this technology area. REDDEN, KAREN M is the only reviewer with 1 pending office action on her docket.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (33%) |
| Multi-statute (no §101) | 2 (67%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| REDDEN, KAREN M | 1 | 88.4% | -21.5% |
| JOHNSON, EMILY KATHARINE | 1 | 87.5% | +21.9% |
| MOAZZAMI, NAGHMEH NINA | 1 | 71.8% | +49.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19100249 | METHODS OF ALTERING THE STARCH GRANULE PROFILE IN PLANTS | REDDEN, KAREN M | — |
| 18871655 | SAPONARIOSIDE BIOSYNTHETIC ENZYMES | JOHNSON, EMILY KATHARINE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18871655 | SAPONARIOSIDE BIOSYNTHETIC ENZYMES | JOHNSON, EMILY KATHARINE | — |
| 18849851 | BIOSYNTHESIS | MOAZZAMI, NAGHMEH NINA | — |
| Art Unit | Apps |
|---|---|
| 1661 | 1 |
| 1662 | 1 |
| 1652 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19100249 | METHODS OF ALTERING THE STARCH GRANULE PROFILE IN PLANTS | REDDEN, KAREN M | 1661 | §102§103 | Non-Final OA | — | Pending | Jan 31, 2025 |
| 18871655 | SAPONARIOSIDE BIOSYNTHETIC ENZYMES | JOHNSON, EMILY KATHARINE | 1662 | §103§112 | Final Rejection | — | Pending | Dec 04, 2024 |
| 18849851 | BIOSYNTHESIS | MOAZZAMI, NAGHMEH NINA | 1652 | §112Other | Non-Final OA | — | Pending | Sep 23, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialPlant Bioscience Limited has 3 pending office actions as of October 2026, spread across 3 art units and 3 examiners.
Karen M Redden has the most, with 1 of Plant Bioscience Limited's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
